CN111116773A - Ganoderma lucidum β glucan GLBG component and preparation process and application thereof - Google Patents
Ganoderma lucidum β glucan GLBG component and preparation process and application thereof Download PDFInfo
- Publication number
- CN111116773A CN111116773A CN202010134606.XA CN202010134606A CN111116773A CN 111116773 A CN111116773 A CN 111116773A CN 202010134606 A CN202010134606 A CN 202010134606A CN 111116773 A CN111116773 A CN 111116773A
- Authority
- CN
- China
- Prior art keywords
- glbg
- ganoderma lucidum
- component
- glucan
- glc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 71
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 71
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 41
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 23
- 239000005017 polysaccharide Substances 0.000 claims abstract description 23
- 150000004676 glycans Chemical class 0.000 claims abstract description 22
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 18
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 9
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- 239000008103 glucose Substances 0.000 abstract description 16
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 abstract description 13
- 229940097043 glucuronic acid Drugs 0.000 abstract description 13
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000012528 membrane Substances 0.000 abstract description 4
- 238000001556 precipitation Methods 0.000 abstract description 4
- 238000000108 ultra-filtration Methods 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 150000002772 monosaccharides Chemical class 0.000 description 7
- 229920001503 Glucan Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000222336 Ganoderma Species 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000004622 sleep time Effects 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960000796 barbital sodium Drugs 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004620 sleep latency Effects 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001149422 Ganoderma applanatum Species 0.000 description 1
- 241001489100 Ganoderma capense Species 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- 241001480597 Ganoderma tsugae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 glucose polysaccharide Chemical class 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Sustainable Development (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a Ganoderma lucidum β glucan GLBG component and a preparation process and application thereof, wherein Ganoderma lucidum refers to Ganoderma lucidum (Leys. ex Fr.) Kars) fruiting body, Ganoderma lucidum for short, and is prepared by the steps of low-temperature wall breaking and crushing, extraction, ultrafiltration membrane concentration, multistage precipitation, intermediate preparation, finished product preparation and the like by taking the Ganoderma lucidum as a raw material, wherein the Ganoderma lucidum β glucan GLBG component is prepared by the polysaccharide β glucan polymerized from glucose and glucuronic acid, and can be used as a raw material for producing foods, health-care products and pharmaceutical preparations, and the invention belongs to the related fields of food processing and pharmaceutical industry.
Description
Technical Field
The invention relates to a Ganoderma lucidum β glucan GLBG component, a preparation process and application thereof, wherein the Ganoderma lucidum refers in particular to Ganoderma lucidum (Leys. ex Fr.) Kars) fruiting body, namely Ganoderma lucidum, which is prepared by the steps of wall breaking, crushing, extracting, concentrating, precipitating, preparing intermediates, preparing finished products and the like by taking the fruiting body as a raw material, wherein the Ganoderma lucidum β glucan GLBG component is a β glucan polymerized by glucose and glucuronic acid and can be used as a raw material for producing foods, health care products and pharmaceutical preparations.
Background
Ganoderma lucidum is a generic name of Ganoderma of Polyporaceae, and is commonly named as Ganoderma sinensis, Ganoderma Applanatum, Ganoderma lucidum, Ganoderma tsugae, Ganoderma capense, etc. Ganoderma lucidum is a traditional Chinese medicine and is recorded in Shennong Ben Cao Jing, Qian jin Yao Fang, Ben Cao gang mu and Chinese pharmacopoeia. Wherein 2015 edition of Chinese pharmacopoeia records red ganoderma and purple ganoderma, which are believed to have the effects of relieving cough and asthma, invigorating qi and tranquilizing mind.
β Glucan is a glucose polysaccharide with β glycosidic linkages, wherein the glucose units are linked in a variety of ways such as 1 → 2, 1 → 3, 1 → 4 and 1 → 6, the molecular weight is distributed from thousands to millions of daltons, and the structure has branched chains in addition to the backbone, which is a complex macromolecule.
β glucan exists widely in cell walls of fungi, ganoderma lucidum is no exception, and there are many reports on β glucan extracted from ganoderma lucidum at home and abroad, but since glucan is a macromolecule with a complex structure, ganoderma lucidum glucan reported in documents is different and has respective characteristics in structure, the ganoderma lucidum glucan is extracted from ganoderma lucidum, wherein the ganoderma lucidum glucan is obtained from ganoderma lucidum (30 nd volume, 1 st stage, pages l 23-127, 1 month in 2010) through spectroscopic analysis, the molecular weight of ganoderma lucidum glucan is between 8 and 20 ten thousand, D-arabinose, D-xylose, D-mannose and D-galactose are also extracted from ganoderma lucidum as main components, besides glucose, phenanthrene and the like (Chinese herbal medicines, 49 th volume, 10 th stage, pages 2359-2364, 5 months in 2018) are also provided, ganoderma lucidum β glucan is extracted from ganoderma lucidum, monosaccharide composition is mainly glucose, and the connection mode is mainly 1 → 3 and 1 → 6.
The ganoderma lucidum β glucan GLBG component is different from related ganoderma lucidum β glucan reported in the past literature, the extraction process adopts a low-temperature wall breaking technology, multiple fractional precipitation, membrane concentration, gel column chromatography and other key steps, and the obtained glucan has the characteristics of moderate molecular weight, good water solubility, easiness in absorption and the like and has biological activities of improving the immunity of an organism, resisting tumors and the like.
Disclosure of Invention
The invention relates to a ganoderma lucidum β glucan GLBG component, which is a specific structural polysaccharide extracted from ganoderma lucidum (Leys. ex Fr.) Kars) fruiting bodies, wherein the polysaccharide of the component is not reported in documents before and belongs to a newly discovered ganoderma lucidum polysaccharide component.
The ganoderma lucidum β glucan GLBG component consists of glucose (β -D-Glc) and glucuronic acid (β -D-GlcA) which are polymerized and connected by 1 → 3 glycosidic bonds, and the molar ratio is 4:1, and the structure of the ganoderma lucidum β glucan GLBG component is the following repeating unit:
-3)β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-GlcA(1→
the molecular weight of the GLBG component is 32589-36584 daltons.
Animal experiments show that the GLGB component has obvious effects on improving immunity and improving sleep, and can be developed into corresponding food, health-care products or medicines.
The preparation process of GLBG is as follows:
firstly, preparing ganoderma lucidum wall-breaking powder
Pulverizing Ganoderma lucidum fruiting body with a pulverizer, sieving with 20 mesh sieve, breaking cell wall of Ganoderma lucidum powder passing through the sieve with cell wall breaking machine at low temperature of-20 deg.C, sieving with 200 mesh sieve, and sieving with the sieve to obtain Ganoderma lucidum cell wall broken powder.
Second, extraction
Weighing a proper amount of ganoderma lucidum wall-broken powder, adding water with the weight being 10 times that of the ganoderma lucidum wall-broken powder, heating to 100 ℃, preserving heat for 2 hours, then filtering, removing residues after solid-liquid separation, and leaving filtrate for later use.
Thirdly, concentration
The proper amount of filtrate for use in the second step of extraction is 2000 Dalton and 10 ten thousand Dalton pores
Treating the ultrafiltration membranes respectively, and taking the part with the weight average molecular weight between 2000 daltons and 10 ten thousand daltons as concentrated solution for later use.
Fourthly, ethanol precipitation
And (3) taking a proper amount of the concentrated solution obtained in the step three and concentrating, adding absolute ethyl alcohol with the volume being 3 times that of the concentrated solution, and stirring while adding. Standing for 2 hr, performing solid-liquid separation by filtration or centrifugation, washing the solid precipitate with 80% ethanol for 2 times, washing with anhydrous ethanol for 2 times, and oven drying to obtain Ganoderma lucidum crude polysaccharide.
Precipitation of CPC (cetylpyridinium chloride)
And (3) adding water with the weight being 10 times of that of the crude polysaccharide obtained in the step four and ethanol precipitation into a proper amount of the crude polysaccharide, heating to 100 ℃, preserving the heat for 2 hours, filtering, removing insoluble substances, adding CPC into the filtrate, stirring and dissolving, wherein the adding amount is 2% of the self weight of the filtrate. Standing for 2 hours until polysaccharide is separated out, centrifuging to obtain precipitate, adding a proper amount of 4% sodium chloride solution into the precipitate, stirring and mixing to dissolve most of the precipitate, centrifuging, discarding insoluble substances to obtain supernatant, adding 3 times of anhydrous ethanol into the supernatant while stirring, standing for 2 hours, centrifuging to obtain precipitate, and drying to obtain the CPC precipitate crude polysaccharide.
Preparation of intermediates of six, GLBG components
The crude polysaccharide from CPC precipitation obtained in the fifth step is carried out by using Sephacryl S-100 HR packed column
Purifying, collecting main peak eluent with the largest peak area, and drying to obtain Ganoderma lucidum β glucan GLBG component intermediate.
Seventhly, preparation of finished product
Using GLBG component intermediate as raw material, and purifying again according to the method of the fifth to sixth steps, namely
Adding water with the weight being 10 times that of a proper amount of GLBG intermediate into a proper amount of GLBG intermediate, heating to 100 ℃, preserving heat for 2 hours, filtering, discarding insoluble substances, adding CPC into filtrate, stirring and dissolving, wherein the adding amount of CPC is 2% of the self weight of the filtrate, standing for 2 hours to separate out polysaccharide, then centrifuging to obtain a precipitate, adding a proper amount of 4% sodium chloride solution into the precipitate, stirring and mixing to dissolve most of the precipitate, then centrifuging, discarding the insoluble substances to obtain a supernatant, adding absolute ethyl alcohol with the volume being 3 times that of the volume of the absolute ethyl alcohol into the supernatant, stirring while adding, standing for 2 hours, centrifuging, drying the obtained precipitate, purifying by using a column filled with Sephacryl S-100 HR, collecting a main peak eluent with the largest peak area, and drying to obtain the finished product of the GLBG of the ganoderma lucidum β glucan.
The structural information experiment of ganoderma lucidum β glucan GLBG component is as follows:
1. monosaccharide composition and polysaccharide content analysis
According to a reference document (Dardy et al, the academic journal of analytical tests, vol.26, No. 2, P206-216), PMP (1-phenyl-3-methyl-5-pyrazolone) derivatization analysis method is adopted to analyze monosaccharide composition of GLBG component of Ganoderma lucidum β glucan, the result shows that monosaccharide composition of GLBG component is glucose and glucuronic acid, the molar ratio of glucose to glucuronic acid is 4:1, the contents of glucose and glucuronic acid in GLBG component are respectively determined by combining with a standard curve made by glucose and glucuronic acid reference substances, the sum of the contents of glucose and glucuronic acid is the polysaccharide content of GLBG component, and 3 batches of contents are all more than 95%.
2. Connection mode
The GLBG fraction of Ganoderma lucidum β was analyzed for ligations using partial methylation in the reference (Jansson P E et al, A practical guide to the methylation analysis of carbohydrates, Chem. Commun, 1976, 8(15): 1-74), which indicated that the glycosidic linkages in the GLBG fraction were 1, 3 linkages.
3. Partial acid hydrolysis
0.5 g of ganoderma lucidum β glucan GLBG sample is taken, 2mL of 0.1mol/L sulfuric acid solution is added, the mixture is sealed, the temperature is kept at 80 ℃ for 15 minutes, the pH value of the solution is adjusted to be nearly neutral by 0.2mol/L sodium hydroxide solution, the solution is dialyzed overnight by running water in a dialysis bag with the intercepted weight-average molecular weight of 4000, partial acid hydrolyzed GLBG component is obtained after the liquid in the bag is dried, and the sugar composition and connection mode analysis are carried out on the hydrolyzed component, so that the hydrolyzed component is consistent with the unhydrolyzed GLBG component, namely the hydrolyzed component is composed of 4:1 glucose and glucuronic acid which are connected by 1, 3 glycosidic bonds.
4. The weight average molecular weight of 3 batches of GLBG is measured by a multi-angle laser light scattering method, and the result shows that the weight average molecular weight of 3 batches of samples is 32589-36584 daltons.
5. Structural analysis
Through the experiments of 1-4, the GLBG component is prepared by connecting glucose and glucuronic acid by 1, 3 glycosidic bonds, the molar ratio of the two is 4:1, the weight average molecular weight is 32589-36584 daltons, and the GLBG component has the following repeating units:
-3)β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-GlcA(1→。
Detailed Description
EXAMPLE 1 preparation of Ganoderma lucidum β Glucan GLBG fraction
Crushing dry ganoderma lucidum sporocarp products by using a crusher, sieving by using a 20-mesh sieve, breaking the wall of ganoderma lucidum powder which can pass through the sieve at a low temperature by using a wall breaking machine, breaking the wall at a temperature of minus 20 ℃, sieving by using a 200-mesh sieve after wall breaking to obtain ganoderma lucidum wall-breaking powder, weighing 1 kg ganoderma lucidum wall-breaking powder, adding 10 kg hot water, uniformly stirring, heating to 100 ℃ for extraction for 2 hours, cooling, filtering by using a plate frame to remove residues to obtain clear extract, performing ultrafiltration on the extract by using ultrafiltration membranes with the weight average molecular weights of 2000 daltons and 10 ten thousand daltons respectively, cutting off a part between the weight average molecular weights of 2000 and 10 ten thousand daltons to obtain concentrated solution, adding 3 times of absolute ethyl alcohol into the concentrated solution, stirring while adding, standing for 2 hours, centrifuging, washing the precipitate for 2 times by using 80% of ethyl alcohol, washing for 2 times by using absolute ethyl alcohol, drying to obtain ganoderma lucidum crude polysaccharide, adding 10 times of water to the obtained crude polysaccharide, heating to 100 ℃, performing heat preservation and extraction for 2 hours, filtering, removing CPC, adding insoluble substances into filtrate, stirring, dissolving and dissolving, adding 2 hours, adding a proper amount of supernatant, adding a proper amount of purified supernatant of purified polysaccharide, centrifuging, drying, and collecting a precipitate, and obtaining a precipitate, and obtaining a supernatant, namely, adding a supernatant, and performing centrifugation, namely, adding a large amount of a supernatant, and drying.
Example 2 structural analysis of Ganoderma lucidum β Glucan GLBG fraction
Structural analysis was performed on 3 batches of GLGB fraction (lots 20180801, 20180802, 20180803) from example 1. PMP (1-phenyl-3-methyl-5-pyrazolone) derivatization method is adopted for analyzing monosaccharide composition and polysaccharide content; the connection mode of the monosaccharide is analyzed by a partial methylation method; the polysaccharide configuration adopts an infrared analysis method; the weight average molecular weight is measured by a multi-angle laser scattering method; respectively carrying out partial acid hydrolysis on the 3 batches of samples to obtain corresponding batches of hydrolysis products 20180801-1, 20180802-1 and 20180803-1, wherein the specific process comprises the following steps: adding 0.5 g of GLGB component into 2mL of 0.1mol/L sulfuric acid solution, sealing, keeping the temperature at 80 ℃ for 15 minutes, and adjusting the pH value of the solution to be nearly neutral by using 0.2mol/L sodium hydroxide solution. Dialyzing with flowing water in dialysis bag with weight average molecular weight of 4000 overnight, drying the liquid in the bag to obtain partial acid hydrolyzed product, and analyzing sugar composition and connection mode of the 3 batches of hydrolyzed product. The test results are shown in the following tables 1-2:
the results of physical and chemical measurements of the GLGB components in 3 batches are shown in Table 1
TABLE 1
| Batch number | 20180801 | 20180802 | 20180803 |
| Molar ratio of | 4.01：1 | 4.05：1 | 3.95：1 |
| Connection mode | 1 → 3 connection | 1 → 3 connection | 1 → 3 connection |
| Weight average molecular weight (Mw) | 32589 | 36584 | 33488 |
| Polysaccharide content | 96% | 96% | 97% |
Note: the "molar ratio" in the table means the ratio of the number of moles of glucose to the number of moles of glucuronic acid in GLGB
The results of the physicochemical measurements of the products of the partial acid hydrolysis of 3 batches are shown in Table 2
TABLE 2
| Batch number | 20180801-1 | 20180802-1 | 20180803-1 |
| Molar ratio of | 4.03：1 | 3.97：1 | 4.02：1 |
| Connection mode | 1 → 3 connection | 1 → 3 connection | 1 → 3 connection |
Note: the "molar ratio" in the table means the ratio of the number of moles of glucose to the number of moles of glucuronic acid in GLGB
The infrared scanning result shows that 3 batches of GLGB samples are 890cm-1All had weak absorption peaks, indicating that the GLGB component is in the β configuration.
According to the results of the above physicochemical measurements, the ganoderma lucidum β glucan GLBG component is prepared by polymerizing 1, 3-linked glucose and glucuronic acid, the molar ratio of the two monosaccharides is 4:1, the weight-average molecular weight is 32589-36584, and the ganoderma lucidum β glucan GLBG component has the following structure:
-3)β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-GlcA(1→。
example 3 preparation of Ganoderma lucidum β Glucan GLBG component tablet
100 g of ganoderma lucidum β glucan GLBG component in example 1 is taken, 100 g of auxiliary materials are added, and the mixture is uniformly mixed, granulated, dried and pressed into 1000 tablets, so that ganoderma lucidum β glucan GLBG component tablets are obtained.
Example 4 preparation of Ganoderma lucidum β Glucan GLBG component capsules
150 g of ganoderma lucidum β glucan GLBG component in example 1 is taken, 150 g of auxiliary materials are added, mixed uniformly, granulated, dried and filled into 1000 capsules, and the ganoderma lucidum β glucan GLBG component capsule is obtained.
Example 5 Ganoderma lucidum β Glucan GLBG fraction having an Immunity enhancing effect
sample-Ganoderma lucidum β Glucan GLBG fraction (polysaccharide content greater than 95%)
Animals: healthy Kunming breed mice 36, male and female half.
Preparing a model: each mouse was injected with 50mg/kg BW (dose converted to body weight, the same applies below) intraperitoneally to prepare a mouse model with low immune function.
The animal grouping and administration mode comprises that 3 groups of a model group, a control group and a tested group are divided into 12 groups, each group has 12 males and females, the mice of the control group are subjected to intragastric administration by 0.9% of normal saline for 14 consecutive days, the mice of the model group and the tested group are subjected to intraperitoneal injection of 50mg/kgBW of cyclophosphamide for 7 consecutive days, and the tested group is subjected to intragastric administration by adding a ganoderma lucidum β glucan GLBG component besides the cyclophosphamide injection, wherein the dose is 2g/kg BW, 1 time per day and 14 consecutive days.
The experimental results are as follows:
the influence of the ganoderma lucidum β glucan GLBG component on the immunity of mice is evaluated by thymus and spleen indexes, natural killer cell (NK) killing activity, IL-2 and IL-4 contents and the like.
The body weight of the mice and the mass of the thymus and spleen are weighed, the mg number of the thymus and spleen corresponding to 10g body weight of the mice, namely the thymus index and spleen index, is calculated, and the result is analyzed by SPSS software, and the weight is shown in a table 3:
TABLE 3
| Group of | Thymus index (mg/10 g) | Spleen index (mg/10 g) |
| Control group | 13.4±1.2 | 30.1±1.9 |
| Model set | 8.1±0.6** | 18.5±0.9** |
| Test group | 11.3±1.1* | 24.7±1.6* |
P <0.05 compared to model group, P <0.01 compared to control group
The natural killer cell (NK) killing activity is determined by adopting a Lactate Dehydrogenase (LDH) release method, the IL-2 and IL-4 contents are determined by adopting an enzyme-linked immunosorbent assay (ELISA), and the specific operation steps refer to the kit specification. The results are shown in Table 4
TABLE 4
| Group of | NK cell killing Activity (%) | IL-2 content (pg/ml) | IL-4 content (pg/ml) |
| Control group | 61.15±4.32 | 45.77±1.92 | 42.16±2.53 |
| Model set | 38.42±3.98** | 31.52±1.67** | 33.07±2.21** |
| Test group | 53.97±4.35* | 41.88±2.09* | 39.91±1.88* |
P <0.05 compared to model group, P <0.01 compared to control group
It can be seen from tables 3 and 4 that there is a significant difference between the model group and the control group (P < 0.01), indicating that the modeling was successful, and there is a significant difference between the test group and the model group (P < 0.05), indicating that the GLBG component is helpful to increase the thymus index and the spleen index, enhance the NK cell killing activity and increase the content of IL-2 and IL-4, i.e. to enhance the immunocompetence of the mice.
Example 6 sleep improving effects of Ganoderma lucidum β Glucan GLBG component
sample-Ganoderma lucidum β Glucan GLBG fraction (polysaccharide content greater than 95%)
Reagent: the reagents were all commercially available analytical grade.
Animals: healthy Kunming mouse 60, male.
Animal grouping and administration mode: the experiment is divided into three parts, namely a direct sleep experiment, a barbiturate sodium sleep latency experiment and a pentobarbital sodium sleep time prolonging experiment, wherein each part of experiment comprises 20 mice, and the experiment is randomly divided into two groups, namely 10 mice in a control group and a tested group.
The direct sleep experiment takes the disappearance of righting reflex as an index, the gastric lavage of the ganoderma lucidum β glucan GLBG component of the tested group and the gastric lavage of the normal saline of the control group are carried out, the dosage is converted into 2g/kg according to the weight, 1 time per day and 30 days continuously, and as a result, the disappearance of the righting reflex of two groups of mice does not appear, and the GLBG component has no direct sleep effect on the mice.
Experiment of sleep latency of barbital sodium
The test group is intragastrically administered with the corresponding GLBG component according to the dose of 2g/kg converted by the weight, the control group is intragastrically administered with the corresponding normal saline for 30 days respectively, each group of mice after the last intragastrically administered with the barbital sodium according to the dose of 270mg/kg converted by the weight are intraperitoneally injected respectively, the time of the mice entering the sleep, namely the latency period, is calculated, and the result shows that the time of the test group entering the sleep is obviously different from that of the control group, namely the GLBG component has a certain effect on reducing the time of the mice entering the sleep, and the specific table 5 shows that:
TABLE 5
| Group of | Sleep time (min) |
| Control group | 25.16±4.33 |
| Test group | 16.71±3.25* |
P <0.05 compared to control group
Experiment for prolonging sleep time of sodium pentobarbital
The test group is intragastrically administered with the corresponding GLBG component according to the dose of 2g/kg converted by the body weight, the control group is intragastrically administered with the corresponding normal saline, the two groups are intragastrically administered for 30 days respectively, each group of mice after the last intragastrically administered with pentobarbital sodium according to the dose of 50mg/kg BW respectively, the continuous sleeping time of each group of mice is recorded, the result shows that the test group is obviously different from the control group, and the GLBG component has a certain effect on prolonging the sleeping time of the mice, which is specifically shown in Table 6:
TABLE 6
| Group of | Duration of sleep (min) |
| Control group | 29.55±5.12 |
| Test group | 45.36±7.44* |
P <0.05 compared to control group
Claims (6)
1. A Ganoderma lucidum β glucan GLBG component is characterized in that the structure is β -D-glucose and β -D-glucuronic acid which are connected by 1 → 3 glycosidic bond, the molar ratio is 4:1, and the Ganoderma lucidum β glucan GLBG component has the following repeating units:
-3)β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-Glc(1→3)-β-D-GlcA(1→。
2. the GLBG fraction of claim 1, wherein the material used for the extraction is Ganoderma lucidum fruit bodies.
3. A process for extracting GLBG components as in claims 1-2, wherein the fruiting body of Ganoderma lucidum is subjected to low temperature wall breaking before extraction, and the precipitating agents used in the extraction process are ethanol and cetylpyridinium chloride.
4. A GLBG component according to claims 1-3, wherein the GLBG component has a weight average molecular weight of 32589-36584 daltons and a total polysaccharide content of greater than 95%.
Use of the GLBG component in the preparation of a food or pharmaceutical product for enhancing immunity.
Use of a GLBG component in the preparation of a food and a pharmaceutical product for improving sleep.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010134606.XA CN111116773A (en) | 2020-03-02 | 2020-03-02 | Ganoderma lucidum β glucan GLBG component and preparation process and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010134606.XA CN111116773A (en) | 2020-03-02 | 2020-03-02 | Ganoderma lucidum β glucan GLBG component and preparation process and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111116773A true CN111116773A (en) | 2020-05-08 |
Family
ID=70493497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010134606.XA Pending CN111116773A (en) | 2020-03-02 | 2020-03-02 | Ganoderma lucidum β glucan GLBG component and preparation process and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111116773A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006037016A (en) * | 2004-07-29 | 2006-02-09 | Shiriusu:Kk | METHOD FOR EXTRACTION OF beta-GLUCAN FROM DEER HORN AND GANODERMA LUCIDUM |
| CN104013652A (en) * | 2013-12-29 | 2014-09-03 | 金华寿仙谷药业有限公司 | Purification process, comprehensive utilization method and application of ganoderma lucidum spores powder |
| CN105175575A (en) * | 2015-10-30 | 2015-12-23 | 上海市农业科学院 | Ganoderma lucidum beta-glucan and preparing method and application thereof |
| CN106146684A (en) * | 2016-07-26 | 2016-11-23 | 海安县泓寿生物技术有限责任公司 | The isolation and purification method of ganoderma spove powder GL-B |
| CN106432527A (en) * | 2016-11-03 | 2017-02-22 | 南京希元生物医药科技有限公司 | Extraction technology of wall-broken ganoderma lucidum spore powder polysaccharide |
| CN106832042A (en) * | 2017-02-03 | 2017-06-13 | 中国科学院上海药物研究所 | The glucans of β 1,3, its preparation method and pharmaceutical applications |
| CN108467438A (en) * | 2018-02-01 | 2018-08-31 | 浙江寿仙谷医药股份有限公司 | Lucidum spore powder wall polysaccharide and its extracting method |
| CN108610435A (en) * | 2018-07-27 | 2018-10-02 | 吉林大学珠海学院 | A kind of ganoderma spore polysaccharide extraction process |
-
2020
- 2020-03-02 CN CN202010134606.XA patent/CN111116773A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006037016A (en) * | 2004-07-29 | 2006-02-09 | Shiriusu:Kk | METHOD FOR EXTRACTION OF beta-GLUCAN FROM DEER HORN AND GANODERMA LUCIDUM |
| CN104013652A (en) * | 2013-12-29 | 2014-09-03 | 金华寿仙谷药业有限公司 | Purification process, comprehensive utilization method and application of ganoderma lucidum spores powder |
| CN105175575A (en) * | 2015-10-30 | 2015-12-23 | 上海市农业科学院 | Ganoderma lucidum beta-glucan and preparing method and application thereof |
| CN106146684A (en) * | 2016-07-26 | 2016-11-23 | 海安县泓寿生物技术有限责任公司 | The isolation and purification method of ganoderma spove powder GL-B |
| CN106432527A (en) * | 2016-11-03 | 2017-02-22 | 南京希元生物医药科技有限公司 | Extraction technology of wall-broken ganoderma lucidum spore powder polysaccharide |
| CN106832042A (en) * | 2017-02-03 | 2017-06-13 | 中国科学院上海药物研究所 | The glucans of β 1,3, its preparation method and pharmaceutical applications |
| CN108467438A (en) * | 2018-02-01 | 2018-08-31 | 浙江寿仙谷医药股份有限公司 | Lucidum spore powder wall polysaccharide and its extracting method |
| CN108610435A (en) * | 2018-07-27 | 2018-10-02 | 吉林大学珠海学院 | A kind of ganoderma spore polysaccharide extraction process |
Non-Patent Citations (3)
| Title |
|---|
| 吴映明等: "超声波-超低温冻融处理对灵芝孢子粉多糖提取的影响 ", 《中国食用菌》 * |
| 钟赣生: "《中药学》", 31 August 2016, 中国中医药出版社 * |
| 黄晓兰等: "破壁与不破壁灵芝孢子粉多糖的分析 ", 《中草药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109400734A (en) | A kind of Polysaccharides from Rosa roxburghii and the preparation method and application thereof | |
| US10835552B2 (en) | Method for preparing linseed polysaccharide having antiviral activity and immunological activity, and use of the linseed polysaccharide | |
| WO2022016644A1 (en) | Acanthopanax senticosus harms homogeneous polysaccharide, preparation method therefor and use thereof | |
| CN108047343B (en) | Preparation method and application of fritillaria pallidiflora total polysaccharide | |
| WO2020093510A1 (en) | Separation and purification method for polysaccharide in ganoderma lucidum spores | |
| CN102408494B (en) | Grifola frondosa polysaccharide ZZK component and preparation method thereof | |
| CN106084087A (en) | A kind of preparation method of Fructus Trichosanthis polysaccharide | |
| CN110343185B (en) | Wine-processed polygonatum polysaccharide and application thereof in regulating spleen deficiency and immune function | |
| CN111410699B (en) | Tibetan ganoderma lucidum polysaccharide GLP-3 and preparation method and application thereof | |
| KR20130010987A (en) | The way of refining panaxan which has efficacies of boosting hematopoiesis and immunity against cancer. and an analysis of defining its attributes and a composition for the efficacies | |
| CN111248440A (en) | Functional jasmine flower oligosaccharide oral liquid and application thereof | |
| JP4098824B2 (en) | Method for physicochemical production of glycogen and glycogen obtained by this method | |
| CN103275237A (en) | Preparation method and application of eggplant branch polysaccharide | |
| CN108424469B (en) | Gorgon fruit kernel polysaccharide and separation and extraction method and application thereof | |
| CN111116773A (en) | Ganoderma lucidum β glucan GLBG component and preparation process and application thereof | |
| JP4059442B2 (en) | Method for physicochemical production of glycogen and glycogen obtained by this method | |
| CN115746156A (en) | Lycium barbarum polysaccharide with immunoregulation function and preparation method thereof | |
| CN112794925B (en) | Amomum villosum polysaccharide and preparation method and application thereof | |
| CN113105567B (en) | Paecilomyces cicadae mannan and preparation and application thereof | |
| CN110483657B (en) | Chinese lobelia homogeneous polysaccharide and preparation method and application thereof | |
| CN111320708B (en) | Reed rhizome polysaccharide and preparation method and application thereof | |
| CN108948223B (en) | Myrtle polysaccharide P1, its separation method and application in preparing hypolipidemic medicine | |
| CN106749732A (en) | Artemisia rupestris extraction method of polysaccharides | |
| CN109234335B (en) | Preparation method of polysaccharide rich in galactofuranose in tabasheer | |
| CN115141288B (en) | Rhizoma anemarrhenae active polysaccharide, rhizoma anemarrhenae crude polysaccharide, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200508 |
|
| WD01 | Invention patent application deemed withdrawn after publication |